The firm continues rapid growth with the addition of industry-recognized experts on cybersecurity, data privacy, and IT risk management talent.

More than 100,000 infusion pumps were found susceptible to severe vulnerabilities that were disclosed roughly three years ago, according to researcher at Palo Alto Networks’ Unit 42.

read more

Business Combination Leverages Strength of Leading Providers of Revenue Cycle Management Services Healthcare Resource Group, Inc. Transaction Highlights: 2021 revenues and adjusted EBITDA of $33.8 million and $3.6 million, respectively 2022 expected revenues and adjusted EBITDA of $40.1 million and $5.2 million, respectively (pre-synergies) Synergies to provide an additional estimated $2.6 million margin improvement to […]

The post CPSI Announces the Acquisition of Healthcare Resource Group, Inc. appeared first on Fintech News.

TOKYO and KENILWORTH, N.J., Feb 25, 2022 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A., for radically unresectable or metastatic renal cell carcinoma (RCC). LENVIMA plus KEYTRUDA is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC. This marks the second approval of this combination in Japan; in December 2021, LENVIMA plus KEYTRUDA was approved for unresectable, advanced or recurrent endometrial carcinoma that progressed after chemotherapy. The approval is based on results from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, in which LENVIMA plus KEYTRUDA demonstrated statistically significant improvements versus sunitinib in the primary efficacy outcome measure of progression-free survival (PFS). Results showed LENVIMA plus KEYTRUDA (n=355) reduced the risk of disease progression or death by 61% (HR=0.39 [95% CI, 0.32-0.49]; p<0.0001), with a median PFS of 23.9 months versus 9.2 months for sunitinib (n=357).

"Nearly one in three cases of renal cell carcinoma are diagnosed at an advanced stage,(1) and patients are in need of new treatment options that may improve survival outcomes,(2)" said Dr. Gregory Lubiniecki, Vice President, Oncology Clinical Research, Merck & Co., Inc., Kenilworth,

N.J., U.S.A. Research Laboratories. "In the CLEAR/KEYNOTE-581 trial, KEYTRUDA plus LENVIMA reduced the risk of disease progression or death by 61% versus sunitinib, a current standard of care. We are encouraged that patients with certain types of advanced renal cell carcinoma may have the opportunity to benefit from this combination."

"Today's milestone for LENVIMA plus KEYTRUDA as a treatment for radically unresectable or metastatic renal cell carcinoma is particularly exciting as it marks the second approval for the combination in Japan," said Terushige Iike, President of Eisai Japan, Senior Vice President, Eisai. "We are thrilled to be able to provide Japanese patients with a new treatment option, illustrating our shared commitment with Merck & Co., Inc., Kenilworth, N.J., U.S.A. to develop therapies with the aim of addressing the unmet needs of those living with difficult-to-treat cancers. We would like to thank the patients, families and healthcare providers who made this approval possible."

The Japanese package inserts for LENVIMA and KEYTRUDA note that in the CLEAR/KEYNOTE-581 trial, adverse reactions were observed in 341 (96.9%) of 352 patients (including 42 of 42 Japanese patients) in the safety analysis set. The most common adverse reactions included diarrhea in 192 patients (54.5%), hypertension in 184 patients (52.3%), hypothyroidism in 150 patients (42.6%), decreased appetite in 123 patients (34.9%), fatigue in 113 patients (32.1%), stomatitis in 113 patients (32.1%), palmar-plantar erythrodysesthesia syndrome in 99 patients (28.1%), proteinuria in 97 patients (27.6%), nausea in 94 patients (26.7%), dysphonia in 87 patients (24.7%), rash in 77 patients (21.9%), and asthenia in 71 patients (20.2%).

Renal cell carcinoma is the most common type of kidney cancer worldwide; about nine out of 10 kidney cancer diagnoses are RCC.(3) In Japan, there were more than 25,000 new cases of kidney cancer diagnosed and more than 8,000 deaths from the disease in 2020.(4) Approximately 30% of patients with RCC will have metastatic disease at diagnosis.(5) Survival is highly dependent on the stage at diagnosis, and with a five-year survival rate of 14% for patients diagnosed with metastatic disease, the prognosis for these patients is poor.(6)

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. continue to study the LENVIMA plus KEYTRUDA combination across several types of cancer with more than 20 clinical trials.

For more information, visit https://www.eisai.com/news/2022/pdf/enews202214pdf.pdf.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA.

DENVER–(BUSINESS WIRE)–The recent acquisition of MarijuanaDoctors.com by health technology company Veriheal for $3 million (USD) just made it easier for ... Read More

The healthtech sector has risen consistently over the past years, but the COVID-19 pandemic undeniably accelerated that growth, acting as a catalyst for investment in an already burgeoning sector. In

The post 6 Healthtech Startups From Singapore to Watch in 2022 appeared first on Fintech Singapore.

The partnership enables participation in North Carolina’s health information exchange (HIE) for thousands of SimplePractice customer practices serving clients using insurance LOS ANGELES–(BUSINESS WIRE)–SimplePractice, an EngageSmart (NYSE: ESMT) solution and industry-leading platform simplifying the health and wellness experience, announced that it has partnered with Smartlink Health Solutions, a pioneer in bidirectional health data exchange via […]

The post SimplePractice Partners with Smartlink Health Solutions to Enable Whole Patient Care in North Carolina appeared first on Fintech News.

Unfortunately, the War on Drugs has made it difficult for African Americans to succeed in the cannabis industry. It’s also harder on Black Americans, who are 4 times more likely to be arrested for marijuana-related charges compared to white people. For them, getting a slice of the cannabis pie is much more challenging. Because of that, and because it’s Black History Month, here are some of the most notable African American pioneers in cannabis that deserve recognition for their achievements in the challenging industry. Let’s allow them to inspire the next generation of African-American cannabis trailblazers:

Radicle Science launches several blinded placebo-controlled clinical trials on rare cannabinoids with 10,000 participants in the first half of 2022 on the heels of completing 25 large-scale CBD studies in 2021. SAN DIEGO–(BUSINESS WIRE)–#cannabinoids—Radicle Science, a transformative healthtech B-corp validating health and wellness products for the first time, will launch history’s first large-scale, blinded, placebo-controlled […]

The post Radicle Science Makes History Again With First Large-Scale Clinical Trials on Rare Cannabinoids, Including THCV, CBN, CBG, and CBC appeared first on Fintech News.

Cybersecurity is a growing concern. In 2018 alone, over 1,200 data breaches were orchestrated and nearly 450 million records were compromised. There will be more pressure to improve cybersecurity as these threats escalate. We have a problem with data security. We are more than 70 years into the digital age. We have found that data […]

The post Data Security Standards Are Evolving in Response to Rising Threats appeared first on SmartData Collective.

Bass, Berry & Sims’ 10th annual Healthcare Fraud & Abuse Review 2021 provides analysis of healthcare fraud enforcement actions, False Claims Act developments and scrutiny of cybersecurity and...

(PRWeb February 10, 2022)

Read the full story at https://www.prweb.com/releases/covid_19_relief_funding_for_healthcare_organizations_will_be_under_the_governments_microscope_in_2022_and_beyond/prweb18488126.htm

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and 12 months ended December 31, 2021.